Can kids get COVID and routine shots on the same day? new study says maybe.
NCT ID NCT06038617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether it's safe to give young children (6 months to 5 years old) their mRNA COVID-19 vaccine at the same time as other routine childhood vaccines. About 347 children took part, and researchers tracked fevers and other side effects for a week after vaccination. The goal was to see if combining shots causes more fevers than giving them separately.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mRNA COVID-19 vaccine (Pfizer or Moderna) and routine childhood vaccines (e.g., MMR, DTaP, polio)
- What this could lead to
- If successful, this could show that giving COVID-19 shots with other routine vaccines on the same day is safe for young children, simplifying vaccination schedules.
- What could go wrong
- This is a completed Phase 4 safety study with 347 children, so results are available. However, it only looked at fever and short-term side effects, not long-term safety or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
347 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 months to 4 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Child 6 months through \<5 years of age at time of enrollment. * Child is due to receive mRNA COVID-19 vaccine and at least one other routinely recommended non-live vaccine per CDC or ACIP recommendations. * Parental/LAR intention of child receiving mRNA COVID-19 vaccine and at least one recommended non-live vaccine. * The parent/LAR must be willing and capable of providing permission for their child to participate through the written informed consent process. * The parent/LAR must be available for follow-up and must at minimum have telephone access. * The parent/LAR must agree to sign a medical release for the child so that study personnel may obtain medical information about the child's health (if needed). * The parent/LAR must be willing to delay COVID-19 vaccination for their child for up to 3 weeks. * The parent/LAR must be able to read English or Spanish. Exclusion Criteria: * History of any seizure (including febrile seizure) or first degree relative (biologic parent or biologic sibling including half-sibling) with a history of febrile seizure. * Contraindication to mRNA COVID-19 vaccine: A history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine or a known diagnosed allergy to a component of COVID-19 vaccine. * A history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of a vaccine administered on the day of study enrollment. * For children receiving DTaP vaccine (alone or combination vaccine): Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not attributable to another identifiable cause, within 7 days of administration of previous dose of DTP or DTaP. * Received any other non-live vaccines within 14 days prior to enrollment or any other live vaccines within 28 days prior to enrollment. * Intention to receive non-COVID-19 non-live or live vaccines during the 4 weeks after Visit 1; vaccines may be administered after enrollment if deemed a personal or public health priority by the health care provider caring for this patient or the study team. * Received prior COVID-19 vaccine as part of a clinical trial. * Received any experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 28 days prior to enrollment in this study or expects to receive an experimental/investigational agent during the study. * A moderate to severe acute illness and/or a reported temperature ≥ 100.4°F (≥38.0°C) within 48 hours prior to enrollment or a temperature (measured by temporal artery thermometer) ≥100.4°F (≥38.0°C) at the time of enrollment. (This may result in a temporary delay of vaccination). * Receipt of an antipyretic medication (acetaminophen or ibuprofen) within 72 hours prior to enrollment (this may result in a temporary delay of vaccination) or planned receipt of a prophylactic antipyretic medication on the day of and/or days following vaccination prior to any measured increase in temperature in anticipation of a fever (this exclusion does not apply if the Parent/LAR indicates they might administer antipyretics or analgesics after vaccination to reduce a fever or pain). * Immunosuppression as a result of an underlying illness or treatment, or use of anti-cancer chemotherapy or radiation therapy since birth. * Long term (at least 14 days of prednisone 2 mg/kg/day or equivalent other glucocorticoid) use of any parenteral steroids or high-dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) within the 6 months prior to enrollment (topical and nasal steroids are allowed). * Has an active case of COVID-19 infection. * History of multisystem inflammatory syndrome (MIS-C). * History of myocarditis or pericarditis. * Has any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol. * Any child or grandchild of a study investigator or study team member.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fever are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centers for Disease Control and Prevention
Atlanta, Georgia, 30333, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Columbia University
New York, New York, 10027, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Kaiser Permanente Northern California
Oakland, California, 94612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Stick-On sensor replace the thermometer?
- Color-Coded triage: a quick way to spot sick kids?
- Could letting fever run its course help brain injury patients?
- New dissolving paracetamol tablet put to the test
- Blood test may spot hidden infections in sick kids
- AI reads your symptom stories to find hidden medical clues